Latest Healthcare It News

Enlitic reports a 48% revenue surge in Q2 FY25, secures a major $50 million partnership with GE HealthCare, and completes a $10 million equity raise, positioning itself for operational break-even by year-end.

ReNerve Limited reported a robust 53% increase in annual revenue, driven by strategic partnerships and new regulatory approvals that broaden its global footprint in nerve repair.

AdNeo Limited reports sustained positive cash flow and strong contract wins, advancing its strategic acquisition of Learnt Global ahead of schedule while securing $5.5 million in new capital.

Micro-X has secured its first supply agreement with a leading US healthcare provider for its Rover Plus mobile radiology system, opening access to over 700 facilities nationwide.

dorsaVi has acquired exclusive global rights to advanced RRAM technology, promising major performance gains in its biomedical sensors, while securing key contracts and raising $2.44 million to fuel US market growth.

Vitrafy Life Sciences reported robust progress in Q4 FY2025, advancing its cryopreservation technology and commercial partnerships while preparing for a pivotal product launch in FY2026.

Noble Helium advances its flagship North Rukwa helium project with a significant resource upgrade, rig exit at no cost, and new funding from key insiders, positioning for a leaner, data-driven drilling campaign.

EMVision Medical Devices reports strong progress in its pivotal trial for the emu™ bedside brain scanner and successful aeromedical testing of its First Responder device, backed by a $5 million government grant and $10.5 million in cash reserves.

Centuria Capital No. 2 Fund confirms full compliance with note terms and stable loan positions in its Q4 FY25 report, reassuring investors amid a steady operational quarter.

Epsilon Healthcare has completed a $6.7 million sale and leaseback of its Southport manufacturing site, significantly reducing debt and securing long-term operational stability.

Paradigm Biopharmaceuticals has advanced its global Phase 3 trial for knee osteoarthritis pain with active patient recruitment in Australia and the US, backed by a $41.2 million convertible note facility. The company also expanded its osteoarthritis portfolio through the acquisition of Proteobioactives and the Pentacoxib™ oral therapy.

Vitasora Health Limited reported a remarkable 226% increase in patient programs and secured an $11 million capital raise, positioning the company for accelerated growth and a path to cash flow breakeven in late 2026.